+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome



Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome



Hepato-Gastroenterology 49(47): 1195-1200



Background/Aims: Primary biliary cirrhosis and autoimmune hepatitis are two main immune-mediated liver diseases. Some patients display characteristics of both diseases, so called overlap syndrome. The aims of this study were to investigate and to compare the clinical and laboratory features and responses to therapy in primary biliary cirrhosis and overlap syndrome. Methodology: Twenty-three patients with primary biliary cirrhosis (21 females, 2 males; median age: 50 years) and 20 with primary biliary cirrhosis-autoimmune hepatitis overlap syndrome (18 females, 2 males; median age: 44 years) were included in the study. All patients with primary biliary cirrhosis were treated with ursodeoxycholic acid. Of patients with overlap syndrome, 16 were treated with ursodeoxycholic acid and 4 with ursodeoxycholic acid plus prednisolone. Histological findings laboratory and clinical data were compared at the baseline and at the 2nd year of treatment. Results: Fatigue and pruritus were the most frequent and comparable symptoms in each group. Serum ALT, AST, gamma-glutamyl transpeptidase, total protein, globulin and gammaglobulin levels were higher in patients with overlap syndrome than those in patients with primary biliary cirrhosis. At the end of the 2nd year of the treatment, ALT normalization was achieved in 12 (52%), alkaline phosphatase in 7 (30%) patients with primary biliary cirrhosis. One of the non-responders to ursodeoxycholic acid therapy had the histological findings of overlap syndrome in her control biopsy. Fibrosis score deteriorated in 50% of the patients. Of ursodeoxycholic acid-treated overlap syndrome patients, 11 completed 2 years of treatment. Three patients were biochemically non-responsive and prednisolone was added to their regimen. Of the remaining 8 patients, 7 (64% of total patients) had normal ALT. Three patients had worse fibrosis score comparing the onset of the treatment. Six of 7 (86%) patients who were given ursodeoxycholic acid plus prednisolone including ursodeoxycholic acid-non-responsives had normal ALT and 2 of 6 biopsy-controlled patients display deterioration of their fibrosis score. Conclusions: Biochemical tests tended to be higher in patients with overlap syndrome comparing to those with primary biliary cirrhosis. Response to ursodeoxycholic acid treatment in patients with overlap syndrome was comparable with that obtained in primary biliary cirrhosis. Therefore it should be the first-line treatment. Non-responsive patients may benefit from the use of ursodeoxycholic acid plus prednisolone combination.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010327968

Download citation: RISBibTeXText

PMID: 12239904


Related references

Biochemical, histological parameters and response to UDCA treatment in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Journal of Hepatology 34(Supplement 1): 216, 2001

Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28(2): 296-301, 1998

Flare-up of autoimmune hepatitis after delivery in a patient with primary biliary cirrhosis: postpartum overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis. Digestive Diseases and Sciences 50(1): 201-206, 2005

The usefulness of IgG and IgM immunostaining of periportal inflammatory cells (plasma cells and lymphocytes) for the distinction of autoimmune hepatitis and primary biliary cirrhosis and their staining pattern in autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. American Journal of Clinical Pathology 133(3): 430-437, 2010

Clinical features of 35 cases of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Zhonghua Gan Zang Bing Za Zhi 13(1): 3-5, 2005

Clinical features of 107 autoimmune hepatitis patients and 30 of them with AIH-primary biliary cirrhosis overlap syndrome. Zhonghua Gan Zang Bing Za Zhi 16(5): 367-371, 2008

Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome. Seminars in Liver Disease 28(1): 128-134, 2008

Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study. Chinese Medical Journal 119(3): 238-241, 2006

Primary biliary cirrhosis and the overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis. Annales de Pathologie 28 Spec No 1(1): S54-S55, 2008

Incipient primary biliary cirrhosis/autoimmune hepatitis overlap or hepatitic form of primary biliary cirrhosis: a case report. Cases Journal 2: 7491, 2009

Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome: therapeutic features in 5 patients. Annales de Medecine Interne 154(1): 7-11, 2003

Reversal of cirrhosis in a patient with primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Digestive Diseases and Sciences 50(1): 167-170, 2005

Clinical and pathological characterization of the overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi 13(1): 6-8, 2005

Clinical and pathological analysis of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Beijing Da Xue Xue Bao. Yi Xue Ban 36(6): 609-611, 2004

Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. Journal of Gastroenterology and Hepatology 19(6): 699-706, 2004